🇺🇸 FDA
Patent

US 7422867

Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein

granted A61KA61K38/1709

Quick answer

US patent 7422867 (Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein) held by Rigel Pharmaceuticals, Inc. expires Mon Sep 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Sep 09 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K38/1709